Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec;14(6):2768-2778.
doi: 10.1002/jcsm.13353. Epub 2023 Oct 30.

D3-creatine dilution, computed tomography and dual-energy X-ray absorptiometry for assessing myopenia and physical function in colon cancer: A cross-sectional study

Affiliations

D3-creatine dilution, computed tomography and dual-energy X-ray absorptiometry for assessing myopenia and physical function in colon cancer: A cross-sectional study

En Cheng et al. J Cachexia Sarcopenia Muscle. 2023 Dec.

Abstract

Background: Low skeletal muscle mass (myopenia) is common in cancer populations and is associated with functional decline and mortality, but prior oncology studies did not assess total body skeletal muscle mass. Instead, they measured surrogates such as cross-sectional area (CSA) of skeletal muscle at L3 from computed tomography (CT) or appendicular lean mass (ALM) from dual-energy X-ray absorptiometry (DXA). D3-creatine (D3Cr) dilution is a non-invasive method to assess total body skeletal muscle mass, which has been examined in a variety of populations but not in cancer. To compare the associations of D3Cr muscle mass, CT CSA, and DXA ALM with myopenia and physical function, we conducted a cross-sectional study among 119 patients with colon cancer (2018-2022).

Methods: For each technique (D3Cr, CT and DXA), myopenia was defined as the lowest sex-specific quartile of its measurement. Physical function was measured by the short physical performance battery and grip strength. We calculated Pearson correlations (r) among three techniques, computed Cohen's kappa coefficients (κ) to assess the agreement of myopenia, and estimated Pearson correlations (r) of three techniques with physical function. All analyses were sex-specific.

Results: Sixty-one (51.3%) participants were male, the mean (standard deviation) age was 56.6 (12.9) years, and most (68.9%) had high physical function (short physical performance battery: ≥11 points). Correlations and myopenia agreement among three techniques were greater in men than women; for example, regarding D3Cr muscle mass versus CT CSA, r was 0.73 (P < 0.001) for men versus 0.45 (P < 0.001) for women, and κ was 0.82 (95% CI: 0.65, 0.99) for men versus 0.24 (95% CI: -0.08, 0.52) for women. Among men, higher D3Cr muscle mass was significantly correlated with faster gait speed (r = 0.43, P < 0.01) and stronger grip strength (r = 0.32, P < 0.05); similar correlations were observed for CT CSA and DXA ALM. However, among women, no measure of muscle or lean mass was significantly associated with physical function.

Conclusions: This is the first study using D3-creatine dilution method to assess muscle mass in a cancer population. Regardless of the techniques used for muscle or lean mass assessment, we observed stronger correlations, greater myopenia agreement, and more significant associations with physical function in men with colon cancer than women. D3Cr, CT and DXA are not interchangeable methods for assessing myopenia and physical function, especially in women with colon cancer. Future studies should consider relative advantages of these techniques and examine the D3-creatine dilution method in other cancer types.

Keywords: Computed tomography; D3-Creatine; Dual-energy X-ray absorptiometry; Muscle; Physical performance; Sex; X-ray.

PubMed Disclaimer

Conflict of interest statement

J.A.M has served as an advisor/consultant to Merck Pharmaceutical and COTA Healthcare. The rest of the authors declare no conflict of interest.

Figures

Figure 1
Figure 1
The flow diagram of colon cancer patients with valid baseline D3‐creatine data. CT, computed tomography; D3Cr, D3‐creatine; DXA, dual X‐ray absorptiometry; FORCE, FOcus on reducing dose‐limiting toxicities in colon cancer with resistance exercise.
Figure 2
Figure 2
The distributiona of D3Cr muscle mass and DXA ALM in men (A) and women (B). ALM, appendicular lean mass; DXA, dual‐energy X‐ray absorptiometry; D3Cr, D3‐creatine. aPanels (A) and (B) refer to the comparison of D3Cr muscle mass and DXA ALM in men and women, respectively.
Figure 3
Figure 3
Scatter plotsa for sarcopenia defined by D3Cr muscle mass, CT CSA, and DXA ALM among men and women with colon cancer. ALM, appendicular lean mass; CT, computed tomography; CSA, cross‐sectional area of skeletal muscle; DXA, dual‐energy X‐ray absorptiometry; D3Cr, D3‐creatine. aPanels (A), (C) and (E) refer to the comparisons of D3‐creatine muscle mass versus CT CSA, D3‐creatine muscle mass versus DXA ALM, and CT CSA versus DXA ALM among men, whereas panels (B), (D) and (F) refer to the same comparisons among women. Cohen's kappa coefficients (κ) were calculated and listed in the above of each figure.

Similar articles

Cited by

References

    1. Johns N, Stephens NA, Fearon KC. Muscle wasting in cancer. Int J Biochem Cell Biol 2013;45:2215–2229. - PubMed
    1. Cespedes Feliciano EM, Lee VS, Prado CM, Meyerhardt JA, Alexeeff S, Kroenke CH, et al. Muscle mass at the time of diagnosis of nonmetastatic colon cancer and early discontinuation of chemotherapy, delays, and dose reductions on adjuvant FOLFOX: The C‐SCANS study. Cancer 2017;123:4868–4877. - PMC - PubMed
    1. Cheng E, Caan B, Cawthon P, Evans WJ, Hellerstein MK, Shankaran M, et al. Body composition, relative dose intensity, and adverse events among patients with colon cancer. Cancer Epidemiol Biomarkers Prev 2023;1538–7755) (Electronic) (In eng), 10.1158/1055-9965.EPI-23-0227 - DOI - PMC - PubMed
    1. Xiao J, Caan BJ, Cespedes Feliciano EM, Meyerhardt JA, Peng PD, Baracos VE, et al. Association of low muscle mass and low muscle radiodensity with morbidity and mortality for colon cancer surgery. JAMA Surg 2020;155:942–949. - PMC - PubMed
    1. Caan BJ, Meyerhardt JA, Kroenke CH, Alexeeff S, Xiao J, Weltzien E, et al. Explaining the obesity paradox: the association between body composition and colorectal cancer survival (C‐SCANS study). Cancer Epidemiol Biomarkers Prev 2017;26:1008–1015. - PMC - PubMed

Publication types